Led · Series A · Aug 2026

Golgenia develops therapeutic strategies that target biological processes in the Golgi apparatus to counteract tumor growth and chemotherapy resistance. Its lead compound is being advanced toward a first pilot clinical trial following the Series A financing. The company has an expanded collaboration with Istituto Nazionale Tumori Regina Elena to explore Golgi-related biology and resistance mechanisms. Golgenia recently raised €1.5 million in a Series A round led by Creadd Ventures with participation from Indaco Venture Partners (via Indaco Bio Lombardia / Lombardia Venture STEP) and Ruby Direct Opportunity Fund SCSP. The funds are earmarked to support clinical development activities for its lead program.

Participated · Series B · Nov 2025

Delvitech is a Swiss deep-tech company that builds AI-powered 3D Automated Optical Inspection (AOI) solutions for electronics manufacturing. Its modular platform employs a self-learning neural-network architecture to classify and identify defects on difficult materials such as transparent adhesives, micro-pitch connectors, and plastic components. Beyond defect detection, the system offers predictive analytics that help manufacturers anticipate errors and improve overall quality-control efficiency. The technology is designed to reduce manual programming, speed deployment, and lower operating costs while remaining industry- and material-agnostic. Delvitech’s products serve customers in automotive, telecommunications, EMS, IoT, pharmaceuticals, defence, and industrial automation markets, with plans to expand into semiconductor inspection. Looking ahead, the company intends to scale globally, prioritising India where it expects to open a manufacturing facility in 2026 and reach a production capacity of more than 200 machines per month by 2030.

Led · Seed · Dec 2023

Aesyra is a clinical-stage medical device company and a spin-off of the Federal Institute of Technology Lausanne (EPFL) that has developed the AesyBite® line of oral appliances. Its system combines an intraoral appliance, proprietary sensors, and AI-driven algorithms trained on over 10 years of sleep research data to measure multiple factors during sleep. The company reports its technology has demonstrated over a 70% reduction in bruxism activity for users. Aesyra intends to use new funding to support further development and the commercialization of the AesyBite products and to accelerate deployment. The company is led by founder and CEO Marco Letizia and is based in Lausanne, Switzerland. Aesyra positions its product as an active, sensor- and algorithm-driven approach to improving patient outcomes for bruxism and sleep apnea. Aesyra is developing AesyBite™, a medical device intended to accurately monitor and actively relieve sleep bruxism. The company has secured intellectual property, developed prototypes and obtained clinical data supporting its technology. Management says the new financing will fund industrialization, clinical validation and commercialization of the product. Aesyra’s technology has multiple applications in dentistry and sleep medicine and the company sees significant partnering opportunities. It works closely with medical experts at the Clinique Universitaire de Médecine Dentaire de Genève and leading opinion leaders in bruxism, dental implantology and sleep medicine. Aesyra is a spin-off of the Laboratory of Life Sciences Electronics at EPFL and is based in Lausanne, Switzerland.